

This policy applies to the following:

Standard Control (SF)	Managed Medicaid Template (MMT)	ACSF Chart (ACSFC)	Medical Benefit	✓	Medicare Part B	Reference #
Preferred Drug Plan Design (PDPD)	Marketplace (MF)	SF Chart (SFC)	Medical Benefit: Biosimilars First	✓	Medicare Part B: Advanced Biosimilars First	6304-D
Advanced Control Specialty (ACSF)	New to Market (NTM)	VF Chart (VFC)	Medical Benefit: Add-on			
Value (VF)	Aetna Health Exchange (AHE)		Medical Benefit: Managed Medicaid			
	IVL					

EXCEPTIONS CRITERIA

PD1/PDL1 PRODUCTS: BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA

PREFERRED PRODUCT: LIBTAYO

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the PD1/PDL1 products specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with a targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. PD1/PDL1 Products

	Product(s)
Preferred*	<ul style="list-style-type: none"> Libtayo (cemiplimab)
Targeted	<ul style="list-style-type: none"> Keytruda (pembrolizumab)

*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

II. EXCEPTION CRITERIA

Coverage for a targeted product is provided when either of the following criteria is met:

- Member has received treatment with the targeted product in the past 365 days.
- Member has a documented intolerable adverse event with the preferred product.

REFERENCES

- Keytruda [package insert]. Rathway, NJ: Merck & Co., Inc.; March 2024.
- Libtayo [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; March 2024.
- Clinical Consult. CVS Caremark Clinical Programs Review: Focus on Oncology Clinical Programs. May 2023.